CVS Health (NYSE:CVS) Price Target Raised to $106.00

17 May 2026, 03:25 by Doug Wharley · The Cerbat Gem

CVS Health (NYSE:CVS – Free Report) had its price objective increased by Morgan Stanley from $93.00 to $106.00 in a research note published on Thursday morning, MarketBeat reports. Morgan Stanley currently has an overweight rating on the pharmacy operator’s stock.

Several other equities research analysts have also issued reports on the company. The Goldman Sachs Group raised their target price on CVS Health from $95.00 to $97.00 and gave the company a “buy” rating in a research report on Thursday, February 12th. Truist Financial raised their target price on CVS Health from $98.00 to $102.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Argus decreased their target price on CVS Health from $91.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, January 28th. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 target price on shares of CVS Health in a research report on Thursday, March 5th. Finally, Barclays raised their target price on CVS Health from $93.00 to $101.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.08.

View Our Latest Research Report on CVS Health

CVS Health Price Performance

Shares of NYSE:CVS opened at $95.95 on Thursday. CVS Health has a 1-year low of $58.50 and a 1-year high of $98.43. The stock has a market cap of $122.42 billion, a PE ratio of 42.27, a price-to-earnings-growth ratio of 0.94 and a beta of 0.60. The stock’s fifty day simple moving average is $78.71 and its two-hundred day simple moving average is $78.59. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS – Get Free Report) last announced its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period last year, the firm posted $2.25 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, analysts forecast that CVS Health will post 7.44 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Thursday, April 23rd. CVS Health’s payout ratio is currently 117.18%.

Insider Transactions at CVS Health

In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Swiss RE Ltd. purchased a new position in CVS Health during the 4th quarter valued at about $26,000. Sankala Group LLC purchased a new position in CVS Health during the 4th quarter valued at about $28,000. Caitong International Asset Management Co. Ltd grew its holdings in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 281 shares in the last quarter. Mcguire Capital Advisors Inc. purchased a new position in shares of CVS Health during the fourth quarter worth about $28,000. Finally, Ares Financial Consulting LLC purchased a new position in shares of CVS Health during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Morgan Stanley raised its price target on CVS Health and kept an overweight rating, signaling confidence in further upside after the company’s stronger-than-expected quarterly results. Morgan Stanley Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
Positive Sentiment: Argus also lifted its outlook for CVS Health, adding to the wave of analyst support that may be helping shares move higher. Argus Issues Positive Forecast for CVS Health (NYSE:CVS) Stock Price
Positive Sentiment: CVS reported solid Q1 2026 earnings recently, beating estimates on both revenue and adjusted EPS, which continues to drive investor optimism about execution and valuation. Here is Why CVS Health (CVS) is One of the Cheap Stocks to Buy For the Next 10 Years
Positive Sentiment: CVS and WGU launched an online pre-pharmacy degree program to help build a stronger pharmacist pipeline, a move that could support long-term staffing and service growth. CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
Neutral Sentiment: CVS advanced its portfolio reset by selling Omnicare after bankruptcy court approval, which simplifies the business and removes an underperforming unit, but also confirms ongoing restructuring. CVS Refocuses On Core Health Platform With Omnicare Sale And Drone Rollout
Neutral Sentiment: CVS also highlighted community and brand-building initiatives in Rhode Island, including its economic impact report and expanded WIC acceptance, which are positive for reputation but less likely to move the stock on their own. CVS Health’s Annual Impact in Rhode Island

About CVS Health

(Get Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.